The IAEA is launching a year-long coordinated research project to develop computed tomography-based guidelines on prostate cancer contouring — a critical step in the cancer treatment process that ...
TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, ...
Profound Medical PROF recently announced the FDA clearance of its Contouring Assistant AI module, designed to enhance the creation of automated treatment plans for prostate cancer using its TULSA-PRO ...
Current guidelines used to plan salvage radiation treatments in patients with local recurrence of prostate cancer should be updated to take into consideration information derived from novel imaging ...
Profound Medical Corp. received U.S. FDA 510(k) clearance for its second transurethral ultrasound ablation (TULSA) module using artificial intelligence. When used with Profound’s TULSA-Pro system, the ...
TORONTO, Oct. 20, 2011 /PRNewswire/ – Segasist Technologies, a Canadian software company developing next-generation image contouring platforms for biomedical applications, is delighted to announce ...
Detailed PSMA PET mapping of cancer recurrence in the prostate bed shows that current radiotherapy contouring guidelines—which determine the target areas for treatment—miss a significant number of ...
Contouring is an important part of the radiotherapy treatment planning process. It involves outlining the target volumes and organs at risk (OAR) to guide radiotherapy so that treatment is effective ...
Microultrasonography for prostate biopsy detected clinically significant cancer at rates comparable to MRI-guided approaches. Detection rates for clinically insignificant cancers did not differ among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback